StockNews.com Downgrades CEL-SCI (NYSE:CVM) to Sell

CEL-SCI (NYSE:CVM) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Wednesday.

CEL-SCI Stock Down 3.7 %

CVM stock opened at $0.60 on Wednesday. CEL-SCI has a 1-year low of $0.54 and a 1-year high of $3.23. The business has a fifty day moving average price of $0.93 and a 200-day moving average price of $1.13. The company has a debt-to-equity ratio of 1.00, a current ratio of 0.64 and a quick ratio of 0.18. The stock has a market capitalization of $38.57 million, a P/E ratio of -1.04 and a beta of 0.69.

Institutional Trading of CEL-SCI

Several large investors have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in CEL-SCI by 5.5% during the first quarter. Vanguard Group Inc. now owns 2,193,327 shares of the company’s stock valued at $4,189,000 after purchasing an additional 113,703 shares during the period. Tidal Investments LLC bought a new stake in CEL-SCI during the first quarter valued at about $27,000. Cutter & CO Brokerage Inc. grew its holdings in CEL-SCI by 29.4% during the second quarter. Cutter & CO Brokerage Inc. now owns 108,445 shares of the company’s stock valued at $126,000 after purchasing an additional 24,634 shares during the period. Thoroughbred Financial Services LLC grew its holdings in CEL-SCI by 140.9% during the second quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock valued at $158,000 after purchasing an additional 80,001 shares during the period. Finally, Black Diamond Financial LLC grew its holdings in CEL-SCI by 35.8% during the second quarter. Black Diamond Financial LLC now owns 72,000 shares of the company’s stock valued at $84,000 after purchasing an additional 19,000 shares during the period. Institutional investors own 12.08% of the company’s stock.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.